Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Rapamycin prevents the development and progression of mutant epidermal growth factor receptor lung tumors with the acquired resistance mutation T790M.

Cell reports - 26 Jun 2014

Kawabata Shigeru, Mercado-Matos José R, Hollander M Christine, Donahue Danielle, Wilson Willie, Regales Lucia, Butaney Mohit, Pao William, Wong Kwok-Kin, Jänne Pasi A, Dennis Phillip A

Abstract excerpt

Lung cancer in never-smokers is an important disease often characterized by mutations in epidermal growth factor receptor (EGFR), yet risk reduction measures and effective chemopreventive strategies have not been established. We identify mammalian target of rapamycin (mTOR) as potentially valuable target for EGFR mutant lung cancer. mTOR is activated in human lung cancers with EGFR mutations, and this increases...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibiotics, Antineoplastic
Share to Disease Progression

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Neoplasm

Share to ErbB Receptors

Share to Lung Neoplasms

Share to Random Allocation

Share to Sirolimus

Share to TOR Serine-Threonine Kinases

Source

Open in PubMed Open full text

Identifiers

PMID: 24931608
DOI: 10.1016/j.celrep.2014.05.039
PMCID: PMC4110638

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Rapamycin prevents the development and progression of mutant epidermal growth factor receptor lung tumors with the acquired resistance mutation T790M.PMID 24931608Read ↗

Identification of a highly effective rapamycin schedule that markedly reduces the size, multiplicity, and phenotypic progression of tobacco carcinogen-induced murine lung tumors.Semantic proximity Read ↗

TSC1 loss synergizes with KRAS activation in lung cancer development in the mouse and confers rapamycin sensitivity.Semantic proximity Read ↗

Inhibition of mammalian target of rapamycin reverses alveolar epithelial neoplasia induced by oncogenic K-ras.Semantic proximity Read ↗

ETV7 is an essential component of a rapamycin-insensitive mTOR complex in cancerSemantic proximity Read ↗

Inhibition of Mammalian Target of Rapamycin by Rapamycin Causes the Regression of Carcinogen-Induced Skin Tumor LesionsSemantic proximity Read ↗

Drug discovery targeting the mTOR pathwaySemantic proximity Read ↗

Mammalian Target of Rapamycin (mTOR) Signalling Pathway-A Potential Target for Cancer Intervention: A Short OverviewSemantic proximity Read ↗

Rapamycin extends maximal lifespan in cancer-prone mice.Semantic proximity Read ↗

Targeting mTOR signaling for lung cancer therapy.Semantic proximity Read ↗

Acquired resistance of EGFR-mutant lung adenocarcinomas to afatinib plus cetuximab is associated with activation of mTORC1.Semantic proximity Read ↗

mTOR inhibitors control the growth of EGFR mutant lung cancer even after acquiring resistance by HGF.Semantic proximity Read ↗

The mammalian target of rapamycin signaling pathway: twists and turns in the road to cancer therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.